Role of microRNAs in Chronic Lymphocytic Leukemia Pathogenesis

doi:10.2174/0929867326666190911114842
摘要

微RNA (miRNAs)是一组小的内源性非编码RNA，参与多种癌症和各种细胞过程，如细胞生长、DNA甲基化、凋亡和分化。13q14.3染色体区域包含miR-15和miR-16，该区域的缺失是慢性淋巴细胞白血病(CLL)中常见的异常，提示miRNAs参与了CLL的发病机制。微RNA在CLL中被称为癌基因和肿瘤抑制因子，它也可能是疾病发生和发展的标志。在西方世界，被诊断为成人最常见的白血病——慢性淋巴细胞白血病，占所有白血病的三分之一。CLL的特征是B细胞恶性克隆存在于次级淋巴组织、外周血和骨髓中。CLL的确切病因尚不清楚，但已经发现了许多染色体异常，如13q14.3、11q和17p的缺失以及12三体染色体的缺失。在这篇综述中，我们对微RNA如何参与CLL的发病机制和疾病进展进行了展望。对CLL发病机制的潜在机制和调控机制的进一步了解，强调了对其在本病中的作用进行进一步研究的必要性。
关键词: 微RNA，发病机制，慢性淋巴细胞白血病，B细胞恶性克隆，染色体异常。
« Previous Next »
[1] 
Pleyer, L.; Egle, A.; Hartmann, T.N.; Greil, R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat. Rev. Clin. Oncol.,  2009, 6(7), 405-418.
[http://dx.doi.org/10.1038/nrclinonc.2009.72] [PMID:  19488076] 
[2] 
Mirzaei, H.; Fathullahzadeh, S.; Khanmohammadi, R.; Darijani, M.; Momeni, F.; Masoudifar, A.; Goodarzi, M.; Mardanshah, O.; Stenvang, J.; Jaafari, M.R.; Mirzaei, H.R. State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia. J. Cell. Physiol.,  2018, 233(2), 888-900.
[http://dx.doi.org/10.1002/jcp.25799] [PMID:  28084621] 
[3] 
Fathullahzadeh, S.; Mirzaei, H.; Honardoost, M.A.; Sahebkar, A.; Salehi, M. Circulating microRNA-192 as a diagnostic biomarker in human chronic lymphocytic leukemia. Cancer Gene Ther.,  2016, 23(10), 327-332.
[http://dx.doi.org/10.1038/cgt.2016.34] [PMID:  27659777] 
[4] 
Bartel, D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell,  2004, 116(2), 281-297.
[http://dx.doi.org/10.1016/s0092-8674(04)00045-5] [PMID:  14744438] 
[5] 
Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell,  1993, 75(5), 843-854.
[http://dx.doi.org/10.1016/0092-8674(93)90529-y] [PMID:  8252621] 
[6] 
Mashreghi, M.; Azarpara, H.; Bazaz, M.R.; Jafari, A.; Masoudifar, A.; Mirzaei, H. Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis. J. Cell. Physiol.,  2018, 233(4), 2949-2965.
[http://dx.doi.org/10.1002/jcp.26049] [PMID:  28608549] 
[7] 
Masoudi, M.S.; Mehrabian, E.; Mirzaei, H. MiR-21: A key player in glioblastoma pathogenesis. J. Cell. Biochem.,  2018, 119(2), 1285-1290.
[http://dx.doi.org/10.1002/jcb.26300] [PMID:  28727188] 
[8] 
Rashidi, B.; Hoseini, Z.; Sahebkar, A.; Mirzaei, H. Anti-atherosclerotic effects of vitamins D and E in suppression of atherogenesis. J. Cell. Physiol.,  2017, 232(11), 2968-2976.
[http://dx.doi.org/10.1002/jcp.25738] [PMID:  27966778] 
[9] 
Rabieian, R.; Boshtam, M.; Zareei, M.; Kouhpayeh, S.; Masoudifar, A.; Mirzaei, H. Plasminogen activator inhibitor type-1 as a regulator of fibrosis. J. Cell. Biochem.,  2018, 19(11), 17-27.
[http://dx.doi.org/10.1002/jcb.26146] [PMID:  28520219] 
[10] 
Mirzaei, H.; Ferns, G.A.; Avan, A.; Mobarhan, M.G. Cytokines and MicroRNA in coronary artery disease. Adv. Clin. Chem.,  2017, 82, 47-70.
[http://dx.doi.org/10.1016/bs.acc.2017.06.004] [PMID:  28939213] 
[11] 
Jafari, S.H.; Saadatpour, Z.; Salmaninejad, A.; Momeni, F.; Mokhtari, M.; Nahand, J.S.; Rahmati, M.; Mirzaei, H. Breast cancer diagnosis: Imaging techniques and biochemical markers. J. Cell. Physiol.,  2018, 233(7), 5200-5213.
[http://dx.doi.org/10.1002/jcp.26379] [PMID:  29219189] 
[12] 
Khani, P.; Nasri, F.; Khani Chamani, F.; Saeidi, F.; Sadri Nahand, J.; Tabibkhooei, A.; Mirzaei, H. Genetic and epigenetic contribution to astrocytic gliomas pathogenesis. J. Neurochem.,  2019, 148(2), 188-203.
[http://dx.doi.org/10.1111/jnc.14616] [PMID:  30347482] 
[13] 
Banikazemi, Z.; Haji, H.A.; Mohammadi, M.; Taheripak, G.; Iranifar, E.; Poursadeghiyan, M.; Moridikia, A.; Rashidi, B.; Taghizadeh, M.; Mirzaei, H. Diet and cancer prevention: Dietary compounds, dietary MicroRNAs, and dietary exosomes. J. Cell. Biochem.,  2018, 119(1), 185-196.
[http://dx.doi.org/10.1002/jcb.26244] [PMID:  28657651] 
[14] 
Golabchi, K.; Soleimani-Jelodar, R.; Aghadoost, N.; Momeni, F.; Moridikia, A.; Nahand, J.S.; Masoudifar, A.; Razmjoo, H.; Mirzaei, H. MicroRNAs in retinoblastoma: Potential diagnostic and therapeutic biomarkers. J. Cell. Physiol.,  2018, 233(4), 3016-3023.
[http://dx.doi.org/10.1002/jcp.26070] [PMID:  28657205] 
[15] 
Simonian, M.; Mosallayi, M.; Mirzaei, H. Circulating miR-21 as novel biomarker in gastric cancer: Diagnostic and prognostic biomarker. J. Cancer Res. Ther.,  2018, 14(2), 475.
[http://dx.doi.org/10.4103/0973-1482.175428] [PMID:  29516946] 
[16] 
Keshavarzi, M.; Sorayayi, S.; Jafar Rezaei, M.; Mohammadi, M.; Ghaderi, A.; Rostamzadeh, A.; Masoudifar, A.; Mirzaei, H. MicroRNAs-based imaging techniques in cancer diagnosis and therapy. J. Cell. Biochem.,  2017, 118(12), 4121-4128.
[http://dx.doi.org/10.1002/jcb.26012] [PMID:  28370207] 
[17] 
Gholamin, S.; Mirzaei, H. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma. J. Cell. Physiol.,  2018, 233(2), 866-879.
[http://dx.doi.org/10.1002/jcp.25793] [PMID:  28145567] 
[18] 
Jamali, L.; Tofigh, R.; Tutunchi, S.; Panahi, G.; Borhani, F.; Akhavan, S.; Nourmohammadi, P.; Ghaderian, S.M.H.; Rasouli, M.; Mirzaei, H. Circulating microRNAs as diagnostic and therapeutic biomarkers in gastric and esophageal cancers. J. Cell. Physiol.,  2018, 233(11), 8538-8538.
[http://dx.doi.org/10.1002/jcp.26850] [PMID:  29923196] 
[19] 
Keshavarzi, M.; Darijani, M. Molecular imaging and oral cancer diagnosis and therapy. J. Cell. Biochem.,  2017, 118(10), 3055-3060.
[http://dx.doi.org/10.1002/jcb.26042] [PMID:  28390191] 
[20] 
Nahand, J.S.; Taghizadeh-Boroujeni, S.; Karimzadeh, M.; Borran, S.; Pourhanifeh, M.H.; Moghoofei, M.; Bokharaei-Salim, F.; Karampoor, S.; Jafari, A.; Asemi, Z.; Tbibzadeh, A.; Namdar, A.; Mirzaei, H. microRNAs: New prognostic, diagnostic, and therapeutic bi-omarkers in cervical cancer. J. Cell. Physiol.,  2019, 234(10), 17064-17099.
[http://dx.doi.org/10.1002/jcp.28457] [PMID:  30891784] 
[21] 
Aghdam, A.M.; Amiri, A.; Salarinia, R.; Masoudifar, A.; Ghasemi, F.; Mirzaei, H. MicroRNAs as diagnostic, prognostic, and therapeutic biomarkers in prostate cancer. Crit. Rev. Eukaryot. Gene Expr.,  2019, 29(2), 127-139.
[http://dx.doi.org/10.1615/CritRevEukaryotGeneExpr.2019025273] [PMID:  31679268] 
[22] 
Shabaninejad, Z.; Yousefi, F.; Movahedpour, A.; Ghasemi, Y.; Dokanehiifard, S.; Rezaei, S.; Aryan, R.; Savardashtaki, A.; Mirzaei, H. Electrochemical-based biosensors for microRNA detection: Nanotechnology comes into view. Anal. Biochem.,  2019, 581, 113349
[http://dx.doi.org/10.1016/j.ab.2019.113349] [PMID:  31254490] 
[23] 
Mirzaei, H. Stroke in women: risk factors and clinical biomarkers. J. Cell. Biochem.,  2017, 118(12), 4191-4202.
[http://dx.doi.org/10.1002/jcb.26130] [PMID:  28498508] 
[24] 
Bartel, D.P. MicroRNAs: target recognition and regulatory functions. Cell,  2009, 136(2), 215-233.
[http://dx.doi.org/10.1016/j.cell.2009.01.002] [PMID:  19167326] 
[25] 
Wightman, B.; Ha, I.; Ruvkun, G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell,  1993, 75(5), 855-862.
[http://dx.doi.org/10.1016/0092-8674(93)90530-4] [PMID:  8252622] 
[26] 
Moussay, E.; Wang, K.; Cho, J-H.; van Moer, K.; Pierson, S.; Paggetti, J.; Nazarov, P.V.; Palissot, V.; Hood, L.E.; Berchem, G.; Galas, D.J. MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA,  2011, 108(16), 6573-6578.
[http://dx.doi.org/10.1073/pnas.1019557108] [PMID:  21460253] 
[27] 
Saeedi Borujeni, M.J.; Esfandiary, E.; Taheripak, G.; Codoner-Franch, P.; Alonso-Iglesias, E.; Mirzaei, H. Molecular aspects of diabetes mellitus: Resistin, microRNA, and exosome. J. Cell. Biochem.,  2018, 119(2), 1257-1272.
[http://dx.doi.org/10.1002/jcb.26271] [PMID:  28688216] 
[28] 
Tavakolizadeh, J.; Roshanaei, K.; Salmaninejad, A.; Yari, R.; Nahand, J.S.; Sarkarizi, H.K.; Mousavi, S.M.; Salarinia, R.; Rahmati, M.; Mousavi, S.F.; Mokhtari, R.; Mirzaei, H. MicroRNAs and exosomes in depression: Potential diagnostic biomarkers. J. Cell. Biochem.,  2018, 119(5), 3783-3797.
[http://dx.doi.org/10.1002/jcb.26599] [PMID:  29236313] 
[29] 
Ferracin, M.; Zagatti, B.; Rizzotto, L.; Cavazzini, F.; Veronese, A.; Ciccone, M.; Saccenti, E.; Lupini, L.; Grilli, A.; De Angeli, C.; Negrini, M.; Cuneo, A. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol. Cancer,  2010, 9(1), 123.
[http://dx.doi.org/10.1186/1476-4598-9-123] [PMID:  20504344] 
[30] 
Cui, B.; Chen, L.; Zhang, S.; Mraz, M.; Fecteau, J-F.; Yu, J.; Ghia, E.M.; Zhang, L.; Bao, L.; Rassenti, L.Z.; Messer, K.; Calin, G.A.; Croce, C.M.; Kipps, T.J. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood,  2014, 124(4), 546-554.
[http://dx.doi.org/10.1182/blood-2014-03-559690] [PMID:  24914134] 
[31] 
Calin, G.A.; Ferracin, M.; Cimmino, A.; Di Leva, G.; Shimizu, M.; Wojcik, S.E.; Iorio, M.V.; Visone, R.; Sever, N.I.; Fabbri, M.; Iuliano, R.; Palumbo, T.; Pichiorri, F.; Roldo, C.; Garzon, R.; Sevignani, C.; Rassenti, L.; Alder, H.; Volinia, S.; Liu, C.G.; Kipps, T.J.; Negrini, M.; Croce, C.M. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med.,  2005, 353(17), 1793-1801.
[http://dx.doi.org/10.1056/NEJMoa050995] [PMID:  16251535] 
[32] 
Vigorito, E.; Perks, K.L.; Abreu-Goodger, C.; Bunting, S.; Xiang, Z.; Kohlhaas, S.; Das, P.P.; Miska, E.A.; Rodriguez, A.; Bradley, A.; Smith, K.G.; Rada, C.; Enright, A.J.; Toellner, K.M.; Maclennan, I.C.; Turner, M. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity,  2007, 27(6), 847-859.
[http://dx.doi.org/10.1016/j.immuni.2007.10.009] [PMID:  18055230] 
[33] 
Orchard, J.A.; Ibbotson, R.E.; Davis, Z.; Wiestner, A.; Rosenwald, A.; Thomas, P.W.; Hamblin, T.J.; Staudt, L.M.; Oscier, D.G. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet,  2004, 363(9403), 105-111.
[http://dx.doi.org/10.1016/S0140-6736(03)15260-9] [PMID:  14726163] 
[34] 
Hallek, M.; Cheson, B.D.; Catovsky, D.; Caligaris-Cappio, F.; Dighiero, G.; Döhner, H.; Hillmen, P.; Keating, M.J.; Montserrat, E.; Rai, K.R.; Kipps, T.J. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood,  2008, 111(12), 5446-5456.
[http://dx.doi.org/10.1182/blood-2007-06-093906] [PMID:  18216293] 
[35] 
Allegra, D.; Bilan, V.; Garding, A.; Döhner, H.; Stilgenbauer, S.; Kuchenbauer, F.; Mertens, D.; Zucknick, M. Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia. Leukemia,  2014, 28(1), 98-107.
[http://dx.doi.org/10.1038/leu.2013.246] [PMID:  23974981] 
[36] 
Asslaber, D.; Piñón, J.D.; Seyfried, I.; Desch, P.; Stöcher, M.; Tinhofer, I.; Egle, A.; Merkel, O.; Greil, R. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood,  2010, 115(21), 4191-4197.
[http://dx.doi.org/10.1182/blood-2009-07-234823] [PMID:  20089965] 
[37] 
Mertens, D.; Wolf, S.; Tschuch, C.; Mund, C.; Kienle, D.; Ohl, S.; Schroeter, P.; Lyko, F.; Döhner, H.; Stilgenbauer, S.; Lichter, P. Allelic silencing at the tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor mechanism. Proc. Natl. Acad. Sci. USA,  2006, 103(20), 7741-7746.
[http://dx.doi.org/10.1073/pnas.0600494103] [PMID:  16684883] 
[38] 
Rossi, S.; Shimizu, M.; Barbarotto, E.; Nicoloso, M.S.; Dimitri, F.; Sampath, D.; Fabbri, M.; Lerner, S.; Barron, L.L.; Rassenti, L.Z.; Jiang, L.; Xiao, L.; Hu, J.; Secchiero, P.; Zauli, G.; Volinia, S.; Negrini, M.; Wierda, W.; Kipps, T.J.; Plunkett, W.; Coombes, K.R.; Abruzzo, L.V.; Keating, M.J.; Calin, G.A. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood,  2010, 116(6), 945-952.
[http://dx.doi.org/10.1182/blood-2010-01-263889] [PMID:  20393129] 
[39] 
Veronese, A.; Pepe, F.; Chiacchia, J.; Pagotto, S.; Lanuti, P.; Veschi, S.; Di Marco, M.; D’Argenio, A.; Innocenti, I.; Vannata, B.; Autore, F.; Marchisio, M.; Wernicke, D.; Verginelli, F.; Leone, G.; Rassenti, L.Z.; Kipps, T.J.; Mariani-Costantini, R.; Laurenti, L.; Croce, C.M.; Visone, R. Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. Leukemia,  2015, 29(1), 86-95.
[http://dx.doi.org/10.1038/leu.2014.139] [PMID:  24732594] 
[40] 
Calin, G.A.; Dumitru, C.D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K.; Rassenti, L.; Kipps, T.; Negrini, M.; Bullrich, F.; Croce, C.M. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA,  2002, 99(24), 15524-15529.
[http://dx.doi.org/10.1073/pnas.242606799] [PMID:  12434020] 
[41] 
Esquela-Kerscher, A.; Slack, F.J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer,  2006, 6(4), 259-269.
[http://dx.doi.org/10.1038/nrc1840] [PMID:  16557279] 
[42] 
Migliazza, A.; Bosch, F.; Komatsu, H.; Cayanis, E.; Martinotti, S.; Toniato, E.; Guccione, E.; Qu, X.; Chien, M.; Murty, V.V.; Gaidano, G.; Inghirami, G.; Zhang, P.; Fischer, S.; Kalachikov, S.M.; Russo, J.; Edelman, I.; Efstratiadis, A.; Dalla-Favera, R. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood,  2001, 97(7), 2098-2104.
[http://dx.doi.org/10.1182/blood.V97.7.2098] [PMID:  11264177] 
[43] 
Bullrich, F.; Fujii, H.; Calin, G.; Mabuchi, H.; Negrini, M.; Pekarsky, Y.; Rassenti, L.; Alder, H.; Reed, J.C.; Keating, M.J.; Kipps, T.J.; Croce, C.M. Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res.,  2001, 61(18), 6640-6648.
[PMID:  11559527] 
[44] 
Kwok, M.; Rawstron, A.; Agathanggelou, A.; Goel, A.; Oldreive, C.; Jones, R.E.; Drennan, S.; Sharma-Oates, A.; Evans, P.; Smith, E. EBCR unresponsiveness and 13q14
duplication underpin spontaneous disease regression in
chronic lymphocytic leukemia. Am. Soc. Hematology, 2017.
[45] 
Cimmino, A.; Calin, G.A.; Fabbri, M.; Iorio, M.V.; Ferracin, M.; Shimizu, M.; Wojcik, S.E.; Aqeilan, R.I.; Zupo, S.; Dono, M.; Rassenti, L.; Alder, H.; Volinia, S.; Liu, C.G.; Kipps, T.J.; Negrini, M.; Croce, C.M. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA,  2005, 102(39), 13944-13949.
[http://dx.doi.org/10.1073/pnas.0506654102] [PMID:  16166262] 
[46] 
Cory, S.; Adams, J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer,  2002, 2(9), 647-656.
[http://dx.doi.org/10.1038/nrc883] [PMID:  12209154] 
[47] 
Liu, Q.; Fu, H.; Sun, F.; Zhang, H.; Tie, Y.; Zhu, J.; Xing, R.; Sun, Z.; Zheng, X. miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res.,  2008, 36(16), 5391-5404.
[http://dx.doi.org/10.1093/nar/gkn522] [PMID:  18701644] 
[48] 
Calin, G.A.; Cimmino, A.; Fabbri, M.; Ferracin, M.; Wojcik, S.E.; Shimizu, M.; Taccioli, C.; Zanesi, N.; Garzon, R.; Aqeilan, R.I.; Alder, H.; Volinia, S.; Rassenti, L.; Liu, X.; Liu, C.G.; Kipps, T.J.; Negrini, M.; Croce, C.M. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc. Natl. Acad. Sci. USA,  2008, 105(13), 5166-5171.
[http://dx.doi.org/10.1073/pnas.0800121105] [PMID:  18362358] 
[49] 
Cutrona, G.; Matis, S.; Colombo, M.; Massucco, C.; Baio, G.; Valdora, F.; Emionite, L.; Fabris, S.; Recchia, A.G.; Gentile, M.; Neumaier, C.E.; Reverberi, D.; Massara, R.; Boccardo, S.; Basso, L.; Salvi, S.; Rosa, F.; Cilli, M.; Zupo, S.; Truini, M.; Tassone, P.; Calabrese, M.; Negrini, M.; Neri, A.; Morabito, F.; Fais, F.; Ferrarini, M. Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy. Leukemia,  2017, 31(9), 1894-1904.
[http://dx.doi.org/10.1038/leu.2016.394] [PMID:  28053325] 
[50] 
Palamarchuk, A.; Efanov, A.; Nazaryan, N.; Santanam, U.; Alder, H.; Rassenti, L.; Kipps, T.; Croce, C.M.; Pekarsky, Y. 13q14 deletions in CLL involve cooperating tumor suppressors. Blood,  2010, 115(19), 3916-3922.
[http://dx.doi.org/10.1182/blood-2009-10-249367] [PMID:  20071661] 
[51] 
Fabbri, M.; Bottoni, A.; Shimizu, M.; Spizzo, R.; Nicoloso, M.S.; Rossi, S.; Barbarotto, E.; Cimmino, A.; Adair, B.; Wojcik, S.E.; Valeri, N.; Calore, F.; Sampath, D.; Fanini, F.; Vannini, I.; Musuraca, G.; Dell’Aquila, M.; Alder, H.; Davuluri, R.V.; Rassenti, L.Z.; Negrini, M.; Nakamura, T.; Amadori, D.; Kay, N.E.; Rai, K.R.; Keating, M.J.; Kipps, T.J.; Calin, G.A.; Croce, C.M. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA,  2011, 305(1), 59-67.
[http://dx.doi.org/10.1001/jama.2010.1919] [PMID:  21205967] 
[52] 
Zenz, T.; Häbe, S.; Denzel, T.; Mohr, J.; Winkler, D.; Bühler, A.; Sarno, A.; Groner, S.; Mertens, D.; Busch, R.; Hallek, M.; Döhner, H.; Stilgenbauer, S. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood,  2009, 114(13), 2589-2597.
[http://dx.doi.org/10.1182/blood-2009-05-224071] [PMID:  19643983] 
[53] 
Dijkstra, M.K.; van Lom, K.; Tielemans, D.; Elstrodt, F.; Langerak, A.W.; van ’t Veer, M.B.; Jongen-Lavrencic, M. 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia,  2009, 23(3), 625-627.
[http://dx.doi.org/10.1038/leu.2008.264] [PMID:  18818704] 
[54] 
Balatti, V.; Tomasello, L.; Rassenti, L.Z.; Veneziano, D.; Nigita, G.; Wang, H-Y.; Thorson, J.A.; Kipps, T.J.; Pekarsky, Y.; Croce, C.M. miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. Blood,  2018, 132(20), 2179-2182.
[http://dx.doi.org/10.1182/blood-2018-04-845115] [PMID:  30242085] 
[55] 
Santanam, U.; Zanesi, N.; Efanov, A.; Costinean, S.; Palamarchuk, A.; Hagan, J.P.; Volinia, S.; Alder, H.; Rassenti, L.; Kipps, T.; Croce, C.M.; Pekarsky, Y. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc. Natl. Acad. Sci. USA,  2010, 107(27), 12210-12215.
[http://dx.doi.org/10.1073/pnas.1007186107] [PMID:  20566844] 
[56] 
Zhu, W.; Shan, X.; Wang, T.; Shu, Y.; Liu, P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int. J. Cancer,  2010, 127(11), 2520-2529.
[http://dx.doi.org/10.1002/ijc.25260] [PMID:  20162574] 
[57] 
Pekarsky, Y.; Santanam, U.; Cimmino, A.; Palamarchuk, A.; Efanov, A.; Maximov, V.; Volinia, S.; Alder, H.; Liu, C-G.; Rassenti, L.; Calin, G.A.; Hagan, J.P.; Kipps, T.; Croce, C.M. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res.,  2006, 66(24), 11590-11593.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-3613] [PMID:  17178851] 
[58] 
Visone, R.; Veronese, A.; Rassenti, L.Z.; Balatti, V.; Pearl, D.K.; Acunzo, M.; Volinia, S.; Taccioli, C.; Kipps, T.J.; Croce, C.M. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood,  2011, 118(11), 3072-3079.
[http://dx.doi.org/10.1182/blood-2011-01-333484] [PMID:  21636858] 
[59] 
Palamarchuk, A.; Yan, P.S.; Zanesi, N.; Wang, L.; Rodrigues, B.; Murphy, M.; Balatti, V.; Bottoni, A.; Nazaryan, N.; Alder, H.; Rassenti, L.; Kipps, T.J.; Freitas, M.; Croce, C.M.; Pekarsky, Y. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proc. Natl. Acad. Sci. USA,  2012, 109(7), 2555-2560.
[http://dx.doi.org/10.1073/pnas.1200003109] [PMID:  22308499] 
[60] 
Mott, J.L.; Kobayashi, S.; Bronk, S.F.; Gores, G.J. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene,  2007, 26(42), 6133-6140.
[http://dx.doi.org/10.1038/sj.onc.1210436] [PMID:  17404574] 
[61] 
Zhao, J-J.; Lin, J.; Lwin, T.; Yang, H.; Guo, J.; Kong, W.; Dessureault, S.; Moscinski, L.C.; Rezania, D.; Dalton, W.S.; Sotomayor, E.; Tao, J.; Cheng, J.Q. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood,  2010, 115(13), 2630-2639.
[http://dx.doi.org/10.1182/blood-2009-09-243147] [PMID:  20086245] 
[62] 
Herling, M.; Patel, K.A.; Khalili, J.; Schlette, E.; Kobayashi, R.; Medeiros, L.J.; Jones, D. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia,  2006, 20(2), 280-285.
[http://dx.doi.org/10.1038/sj.leu.2404017] [PMID:  16341048] 
[63] 
Faraoni, I.; Antonetti, F.R.; Cardone, J.; Bonmassar, E. miR-155 gene: a typical multifunctional microRNA. Biochim. Biophys. Acta,  2009, 1792(6), 497-505.
[http://dx.doi.org/10.1016/j.bbadis.2009.02.013] [PMID:  19268705] 
[64] 
Ferrajoli, A.; Shanafelt, T.D.; Ivan, C.; Shimizu, M.; Rabe, K.G.; Nouraee, N.; Ikuo, M.; Ghosh, A.K.; Lerner, S.; Rassenti, L.Z.; Xiao, L.; Hu, J.; Reuben, J.M.; Calin, S.; You, M.J.; Manning, J.T.; Wierda, W.G.; Estrov, Z.; O’Brien, S.; Kipps, T.J.; Keating, M.J.; Kay, N.E.; Calin, G.A. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood,  2013, 122(11), 1891-1899.
[http://dx.doi.org/10.1182/blood-2013-01-478222] [PMID:  23821659] 
[65] 
Thai, T.H.; Calado, D.P.; Casola, S.; Ansel, K.M.; Xiao, C.; Xue, Y.; Murphy, A.; Frendewey, D.; Valenzuela, D.; Kutok, J.L.; Schmidt-Supprian, M.; Rajewsky, N.; Yancopoulos, G.; Rao, A.; Rajewsky, K. Regulation of the germinal center response by microRNA-155. Science,  2007, 316(5824), 604-608.
[http://dx.doi.org/10.1126/science.1141229] [PMID:  17463289] 
[66] 
Guinn, D.; Ruppert, A.S.; Maddocks, K.; Jaglowski, S.; Gordon, A.; Lin, T.S.; Larson, R.; Marcucci, G.; Hertlein, E.; Woyach, J.; Johnson, A.J.; Byrd, J.C. miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton’s tyrosine kinase inhibition with Ibrutinib. Leukemia,  2015, 29(5), 1210-1213.
[http://dx.doi.org/10.1038/leu.2014.344] [PMID:  25486872] 
[67] 
Lu, J.; Guo, S.; Ebert, B.L.; Zhang, H.; Peng, X.; Bosco, J.; Pretz, J.; Schlanger, R.; Wang, J.Y.; Mak, R.H.; Dombkowski, D.M.; Preffer, F.I.; Scadden, D.T.; Golub, T.R. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev. Cell,  2008, 14(6), 843-853.
[http://dx.doi.org/10.1016/j.devcel.2008.03.012] [PMID:  18539114] 
[68] 
Xiao, C.; Calado, D.P.; Galler, G.; Thai, T.H.; Patterson, H.C.; Wang, J.; Rajewsky, N.; Bender, T.P.; Rajewsky, K. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell,  2007, 131(1), 146-159.
[http://dx.doi.org/10.1016/j.cell.2007.07.021] [PMID:  17923094] 
[69] 
Mraz, M.; Chen, L.; Rassenti, L.Z.; Ghia, E.M.; Li, H.; Jepsen, K.; Smith, E.N.; Messer, K.; Frazer, K.A.; Kipps, T.J. miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood,  2014, 124(1), 84-95.
[http://dx.doi.org/10.1182/blood-2013-09-527234] [PMID:  24787006] 
[70] 
Stamatopoulos, B.; Van Damme, M.; Crompot, E.; Dessars, B.; Housni, H.E.; Mineur, P.; Meuleman, N.; Bron, D.; Lagneaux, L. Opposite prognostic significance of cellular and serum circulating microRNA-150 in patients with chronic lymphocytic leukemia. Mol. Med.,  2015, 21(1), 123-133.
[http://dx.doi.org/10.2119/molmed.2014.00214] [PMID:  25584781] 
[71] 
Li, S.; Moffett, H.F.; Lu, J.; Werner, L.; Zhang, H.; Ritz, J.; Neuberg, D.; Wucherpfennig, K.W.; Brown, J.R.; Novina, C.D. MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS One,  2011, 6(3), e16956
[http://dx.doi.org/10.1371/journal.pone.0016956] [PMID:  21408091] 
[72] 
Mraz, M.; Kipps, T.J. MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia. Leuk. Lymphoma,  2013, 54(8), 1836-1839.
[http://dx.doi.org/10.3109/10428194.2013.796055] [PMID:  23597135] 
[73] 
Fulci, V.; Chiaretti, S.; Goldoni, M.; Azzalin, G.; Carucci, N.; Tavolaro, S.; Castellano, L.; Magrelli, A.; Citarella, F.; Messina, M.; Maggio, R.; Peragine, N.; Santangelo, S.; Mauro, F.R.; Landgraf, P.; Tuschl, T.; Weir, D.B.; Chien, M.; Russo, J.J.; Ju, J.; Sheridan, R.; Sander, C.; Zavolan, M.; Guarini, A.; Foà, R.; Macino, G. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood,  2007, 109(11), 4944-4951.
[http://dx.doi.org/10.1182/blood-2006-12-062398] [PMID:  17327404] 
[74] 
Xiao, C.; Srinivasan, L.; Calado, D.P.; Patterson, H.C.; Zhang, B.; Wang, J.; Henderson, J.M.; Kutok, J.L.; Rajewsky, K. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat. Immunol.,  2008, 9(4), 405-414.
[http://dx.doi.org/10.1038/ni1575] [PMID:  18327259] 
[75] 
Fedeli, M.; Riba, M.; Garcia Manteiga, J.M.; Tian, L.; Viganò, V.; Rossetti, G.; Pagani, M.; Xiao, C.; Liston, A.; Stupka, E.; Cittaro, D.; Abrignani, S.; Provero, P.; Dellabona, P.; Casorati, G. miR-17∼92 family clusters control iNKT cell ontogenesis via modulation of TGF-β signaling. Proc. Natl. Acad. Sci. USA,  2016, 113(51), E8286-E8295.
[http://dx.doi.org/10.1073/pnas.1612024114] [PMID:  27930306] 
[76] 
Ivanovska, I.; Ball, A.S.; Diaz, R.L.; Magnus, J.F.; Kibukawa, M.; Schelter, J.M.; Kobayashi, S.V.; Lim, L.; Burchard, J.; Jackson, A.L.; Linsley, P.S.; Cleary, M.A. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol. Cell. Biol.,  2008, 28(7), 2167-2174.
[http://dx.doi.org/10.1128/MCB.01977-07] [PMID:  18212054] 
[77] 
O’Donnell, K.A.; Wentzel, E.A.; Zeller, K.I.; Dang, C.V.; Mendell, J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature,  2005, 435(7043), 839-843.
[http://dx.doi.org/10.1038/nature03677] [PMID:  15944709] 
[78] 
Ventura, A.; Young, A.G.; Winslow, M.M.; Lintault, L.; Meissner, A.; Erkeland, S.J.; Newman, J.; Bronson, R.T.; Crowley, D.; Stone, J.R.; Jaenisch, R.; Sharp, P.A.; Jacks, T. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell,  2008, 132(5), 875-886.
[http://dx.doi.org/10.1016/j.cell.2008.02.019] [PMID:  18329372] 
[79] 
Koralov, S.B.; Muljo, S.A.; Galler, G.R.; Krek, A.; Chakraborty, T.; Kanellopoulou, C.; Jensen, K.; Cobb, B.S.; Merkenschlager, M.; Rajewsky, N.; Rajewsky, K. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell,  2008, 132(5), 860-874.
[http://dx.doi.org/10.1016/j.cell.2008.02.020] [PMID:  18329371] 
[80] 
Wong, P.; Iwasaki, M.; Somervaille, T.C.; Ficara, F.; Carico, C.; Arnold, C.; Chen, C-Z.; Cleary, M.L. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res.,  2010, 70(9), 3833-3842.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-3268] [PMID:  20406979] 
[81] 
Bloomston, M.; Frankel, W.L.; Petrocca, F.; Volinia, S.; Alder, H.; Hagan, J.P.; Liu, C-G.; Bhatt, D.; Taccioli, C.; Croce, C.M. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA,  2007, 297(17), 1901-1908.
[http://dx.doi.org/10.1001/jama.297.17.1901] [PMID:  17473300] 
[82] 
Garzon, R.; Volinia, S.; Liu, C-G.; Fernandez-Cymering, C.; Palumbo, T.; Pichiorri, F.; Fabbri, M.; Coombes, K.; Alder, H.; Nakamura, T.; Flomenberg, N.; Marcucci, G.; Calin, G.A.; Kornblau, S.M.; Kantarjian, H.; Bloomfield, C.D.; Andreeff, M.; Croce, C.M. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood,  2008, 111(6), 3183-3189.
[http://dx.doi.org/10.1182/blood-2007-07-098749] [PMID:  18187662] 
[83] 
Schetter, A.J.; Leung, S.Y.; Sohn, J.J.; Zanetti, K.A.; Bowman, E.D.; Yanaihara, N.; Yuen, S.T.; Chan, T.L.; Kwong, D.L.; Au, G.K.; Liu, C.G.; Calin, G.A.; Croce, C.M.; Harris, C.C. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA,  2008, 299(4), 425-436.
[http://dx.doi.org/10.1001/jama.299.4.425] [PMID:  18230780] 
[84] 
Felli, N.; Fontana, L.; Pelosi, E.; Botta, R.; Bonci, D.; Facchiano, F.; Liuzzi, F.; Lulli, V.; Morsilli, O.; Santoro, S.; Valtieri, M.; Calin, G.A.; Liu, C.G.; Sorrentino, A.; Croce, C.M.; Peschle, C. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc. Natl. Acad. Sci. USA,  2005, 102(50), 18081-18086.
[http://dx.doi.org/10.1073/pnas.0506216102] [PMID:  16330772] 
[85] 
Calin, G.A.; Liu, C-G.; Sevignani, C.; Ferracin, M.; Felli, N.; Dumitru, C.D.; Shimizu, M.; Cimmino, A.; Zupo, S.; Dono, M.; Dell’Aquila, M.L.; Alder, H.; Rassenti, L.; Kipps, T.J.; Bullrich, F.; Negrini, M.; Croce, C.M. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl. Acad. Sci. USA,  2004, 101(32), 11755-11760.
[http://dx.doi.org/10.1073/pnas.0404432101] [PMID:  15284443] 
[86] 
Iorio, M.V.; Ferracin, M.; Liu, C-G.; Veronese, A.; Spizzo, R.; Sabbioni, S.; Magri, E.; Pedriali, M.; Fabbri, M.; Campiglio, M.; Ménard, S.; Palazzo, J.P.; Rosenberg, A.; Musiani, P.; Volinia, S.; Nenci, I.; Calin, G.A.; Querzoli, P.; Negrini, M.; Croce, C.M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res.,  2005, 65(16), 7065-7070.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-1783] [PMID:  16103053] 
[87] 
Frenquelli, M.; Muzio, M.; Scielzo, C.; Fazi, C.; Scarfò, L.; Rossi, C.; Ferrari, G.; Ghia, P.; Caligaris-Cappio, F. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood,  2010, 115(19), 3949-3959.
[http://dx.doi.org/10.1182/blood-2009-11-254656] [PMID:  20203269] 
[88] 
Monteleone, N.J.; Lutz, C.S. miR-708-5p: a microRNA with emerging roles in cancer. Oncotarget,  2017, 8(41), 71292-71316.
[http://dx.doi.org/10.18632/oncotarget.19772] [PMID:  29050362] 
[89] 
Dürig, J.; Naschar, M.; Schmücker, U.; Renzing-Köhler, K.; Hölter, T.; Hüttmann, A.; Dührsen, U. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia,  2002, 16(1), 30-35.
[http://dx.doi.org/10.1038/sj.leu.2402339] [PMID:  11840260] 
[90] 
Baer, C.; Oakes, C.C.; Ruppert, A.S.; Claus, R.; Kim-Wanner, S.Z.; Mertens, D.; Zenz, T.; Stilgenbauer, S.; Byrd, J.C.; Plass, C. Epigenetic silencing of miR-708 enhances NF-κB signaling in chronic lymphocytic leukemia. Int. J. Cancer,  2015, 137(6), 1352-1361.
[http://dx.doi.org/10.1002/ijc.29491] [PMID:  25704289] 
[91] 
Baer, C.; Claus, R.; Frenzel, L.P.; Zucknick, M.; Park, Y.J.; Gu, L.; Weichenhan, D.; Fischer, M.; Pallasch, C.P.; Herpel, E.; Rehli, M.; Byrd, J.C.; Wendtner, C.M.; Plass, C. Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia. Cancer Res.,  2012, 72(15), 3775-3785.
[http://dx.doi.org/10.1158/0008-5472.CAN-12-0803] [PMID:  22710432] 
[92] 
Rossi, D.; Rasi, S.; Fabbri, G.; Spina, V.; Fangazio, M.; Forconi, F.; Marasca, R.; Laurenti, L.; Bruscaggin, A.; Cerri, M.; Monti, S.; Cresta, S.; Famà, R.; De Paoli, L.; Bulian, P.; Gattei, V.; Guarini, A.; Deaglio, S.; Capello, D.; Rabadan, R.; Pasqualucci, L.; Dalla-Favera, R.; Foà, R.; Gaidano, G. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood,  2012, 119(2), 521-529.
[http://dx.doi.org/10.1182/blood-2011-09-379966] [PMID:  22077063] 
[93] 
Peter, M.E.; Hadji, A.; Murmann, A.E.; Brockway, S.; Putzbach, W.; Pattanayak, A.; Ceppi, P. The role of CD95 and CD95 ligand in cancer. Cell Death Differ.,  2015, 22(4), 549-559.
[http://dx.doi.org/10.1038/cdd.2015.3] [PMID:  25656654] 
[94] 
Berg, V.; Rusch, M.; Vartak, N.; Jüngst, C.; Schauss, A.; Waldmann, H.; Hedberg, C.; Pallasch, C.P.; Bastiaens, P.I.; Hallek, M.; Wendtner, C.M.; Frenzel, L.P. miRs-138 and -424 control palmitoylation-dependent CD95-mediated cell death by targeting acyl protein thioesterases 1 and 2 in CLL. Blood,  2015, 125(19), 2948-2957.
[http://dx.doi.org/10.1182/blood-2014-07-586511] [PMID:  25670628] 
[95] 
Mraz, M.; Dolezalova, D.; Plevova, K.; Stano Kozubik, K.; Mayerova, V.; Cerna, K.; Musilova, K.; Tichy, B.; Pavlova, S.; Borsky, M.; Verner, J.; Doubek, M.; Brychtova, Y.; Trbusek, M.; Hampl, A.; Mayer, J.; Pospisilova, S. MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. Blood,  2012, 119(9), 2110-2113.
[http://dx.doi.org/10.1182/blood-2011-11-394874] [PMID:  22234685] 
[96] 
Yang, Y-Q.; Tian, T.; Zhu, H-Y.; Liang, J-H.; Wu, W.; Wu, J-Z.; Xia, Y.; Wang, L.; Fan, L.; Li, J-Y.; Xu, W. NDRG2 mRNA levels and miR-28-5p and miR-650 activity in chronic lymphocytic leukemia. BMC Cancer,  2018, 18(1), 1009.
[http://dx.doi.org/10.1186/s12885-018-4915-3] [PMID:  30348117] 
[97] 
Akao, Y.; Nakagawa, Y.; Kitade, Y.; Kinoshita, T.; Naoe, T. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci.,  2007, 98(12), 1914-1920.
[http://dx.doi.org/10.1111/j.1349-7006.2007.00618.x] [PMID:  17892514] 
[98] 
Wang, J.; Yin, D.; Xie, C.; Zheng, T.; Liang, Y.; Hong, X.; Lu, Z.; Song, X.; Song, R.; Yang, H.; Sun, B.; Bhatta, N.; Meng, X.; Pan, S.; Jiang, H.; Liu, L. The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-Myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway. Oncotarget,  2014, 5(18), 8478-8491.
[http://dx.doi.org/10.18632/oncotarget.2328] [PMID:  25261367] 
[99] 
Ichikawa, T.; Nakahata, S.; Fujii, M.; Iha, H.; Morishita, K. Loss of NDRG2 enhanced activation of the NF-κB pathway by PTEN and NIK phosphorylation for ATL and other cancer development. Sci. Rep.,  2015, 5, 12841.
[http://dx.doi.org/10.1038/srep12841] [PMID:  26269411] 
[100] 
Calin, G.A.; Croce, C.M. Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood,  2009, 114(23), 4761-4770.
[http://dx.doi.org/10.1182/blood-2009-07-192740] [PMID:  19745066] 
[101] 
Sachdeva, M.; Zhu, S.; Wu, F.; Wu, H.; Walia, V.; Kumar, S.; Elble, R.; Watabe, K.; Mo, Y.Y. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl. Acad. Sci. USA,  2009, 106(9), 3207-3212.
[http://dx.doi.org/10.1073/pnas.0808042106] [PMID:  19202062] 
[102] 
Wang, L.Q.; Kwong, Y.L.; Kho, C.S.B.; Wong, K.F.; Wong, K.Y.; Ferracin, M.; Calin, G.A.; Chim, C.S. Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia--implications on constitutive activation of NFκB pathway. Mol. Cancer,  2013, 12(1), 173.
[http://dx.doi.org/10.1186/1476-4598-12-173] [PMID:  24373626] 
[103] 
Filip, A.A.; Grenda, A.; Popek, S.; Koczkodaj, D.; Michalak-Wojnowska, M.; Budzyński, M.; Wąsik-Szczepanek, E.; Zmorzyński, S.; Karczmarczyk, A.; Giannopoulos, K. Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle. Ann. Hematol.,  2017, 96(1), 33-50.
[http://dx.doi.org/10.1007/s00277-016-2840-6] [PMID:  27730344] 
[104] 
Kawaguchi, T.; Komatsu, S.; Ichikawa, D.; Tsujiura, M.; Takeshita, H.; Hirajima, S.; Miyamae, M.; Okajima, W.; Ohashi, T.; Imamura, T.; Kiuchi, J.; Konishi, H.; Shiozaki, A.; Okamoto, K.; Otsuji, E. Circulating microRNAs: a next-generation clinical biomarker for digestive system cancers. Int. J. Mol. Sci.,  2016, 17(9), 1459.
[http://dx.doi.org/10.3390/ijms17091459] [PMID:  27598137] 
[105] 
Balatti, V.; Pekarky, Y.; Croce, C.M. Role of microRNA in chronic lymphocytic leukemia onset and progression. J. Hematol. Oncol.,  2015, 8, 12.
[http://dx.doi.org/10.1186/s13045-015-0112-x] [PMID:  25886051] 
[106] 
Patki, M.; Chari, V.; Sivakumaran, S.; Gonit, M.; Trumbly, R.; Ratnam, M. The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells. J. Biol. Chem.,  2013, 288(16), 11047-11065.
[http://dx.doi.org/10.1074/jbc.M112.438473] [PMID:  23426362] 
[107] 
Yang, S-H.; Jaffray, E.; Hay, R.T.; Sharrocks, A.D. Dynamic interplay of the SUMO and ERK pathways in regulating Elk-1 transcriptional activity. Mol. Cell,  2003, 12(1), 63-74.
[http://dx.doi.org/10.1016/S1097-2765(03)00265-X] [PMID:  12887893] 
[108] 
Kefas, B.; Comeau, L.; Floyd, D.H.; Seleverstov, O.; Godlewski, J.; Schmittgen, T.; Jiang, J.; diPierro, C.G.; Li, Y.; Chiocca, E.A.; Lee, J.; Fine, H.; Abounader, R.; Lawler, S.; Purow, B. The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J. Neurosci.,  2009, 29(48), 15161-15168.
[http://dx.doi.org/10.1523/JNEUROSCI.4966-09.2009] [PMID:  19955368] 
[109] 
Rowntree, C.; Duke, V.; Panayiotidis, P.; Kotsi, P.; Palmisano, G.L.; Hoffbrand, A.V.; Foroni, L. Deletion analysis of chromosome 13q14.3 and characterisation of an alternative splice form of LEU1 in B cell chronic lymphocytic leukemia. Leukemia,  2002, 16(7), 1267-1275.
[http://dx.doi.org/10.1038/sj.leu.2402551] [PMID:  12094250] 
[110] 
Burr, M.L.; Sparbier, C.E.; Chan, Y-C.; Williamson, J.C.; Woods, K.; Beavis, P.A.; Lam, E.Y.N.; Henderson, M.A.; Bell, C.C.; Stolzenburg, S.; Gilan, O.; Bloor, S.; Noori, T.; Morgens, D.W.; Bassik, M.C.; Neeson, P.J.; Behren, A.; Darcy, P.K.; Dawson, S.J.; Voskoboinik, I.; Trapani, J.A.; Cebon, J.; Lehner, P.J.; Dawson, M.A. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature,  2017, 549(7670), 101-105.
[http://dx.doi.org/10.1038/nature23643] [PMID:  28813417] 
[111] 
Li, J.; Qin, Y.; Zhang, H. Identification of key miRNA-gene pairs in chronic lymphocytic leukemia through integrated analysis of mRNA and miRNA microarray. Oncol. Lett.,  2018, 15(1), 361-367.
[PMID:  29285196] 
[112] 
Bresin, A.; Callegari, E.; D’Abundo, L.; Cattani, C.; Bassi, C.; Zagatti, B.; Narducci, M.G.; Caprini, E.; Pekarsky, Y.; Croce, C.M.; Sabbioni, S.; Russo, G.; Negrini, M. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model. Oncotarget,  2015, 6(23), 19807-19818.
[http://dx.doi.org/10.18632/oncotarget.4415] [PMID:  26090867] 
[113] 
Dereani, S.; Macor, P.; D’Agaro, T.; Mezzaroba, N.; Dal-Bo, M.; Capolla, S.; Zucchetto, A.; Tissino, E.; Del Poeta, G.; Zorzet, S.; Gattei, V.; Bomben, R. Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. J. Hematol. Oncol.,  2014, 7(1), 79.
[http://dx.doi.org/10.1186/s13045-014-0079-z] [PMID:  25339346] 
[114] 
Zenz, T.; Mohr, J.; Eldering, E.; Kater, A.P.; Bühler, A.; Kienle, D.; Winkler, D.; Dürig, J.; van Oers, M.H.; Mertens, D.; Döhner, H.; Stilgenbauer, S. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood,  2009, 113(16), 3801-3808.
[http://dx.doi.org/10.1182/blood-2008-08-172254] [PMID:  18941118] 
[115] 
Sandhu, S.K.; Fassan, M.; Volinia, S.; Lovat, F.; Balatti, V.; Pekarsky, Y.; Croce, C.M. B-cell malignancies in microRNA Eμ-miR-17~92 transgenic mice. Proc. Natl. Acad. Sci. USA,  2013, 110(45), 18208-18213.
[http://dx.doi.org/10.1073/pnas.1315365110] [PMID:  24145403] 
Rights & Permissions Print Cite
Article Metrics
21
1
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/0929867326666190911114842	Print ISSN 0929-8673
Publisher Name Bentham Science Publisher	Online ISSN 1875-533X
当代药物化学

微RNA在慢性淋巴细胞白血病发病机制中的作用

摘要

当代药物化学

微RNA在慢性淋巴细胞白血病发病机制中的作用

摘要 Play Pause

Related Journals

Related Books

Related Articles

摘要
